Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
4
×
pfizer
4
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
4
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
cancer
eli lilly
medical devices
microbiome
opioids
abbvie
alexion pharmaceuticals
astrazeneca
bridgebio
bristol-myers squibb
What
bio
roundup
drug
drugs
new
acquisitions
advantages
august
bails
bar
biggest
biotech
brand
bridgebio
brings
build
busy
buy
capital
car
ceo
company’s
daniel
days
debut
decisions
develop
devices
dyne’s
emerges
expect
fda
firm
gamble
gilead
grab
headlines
ichnos
invest
legacy
Language
unset
4
×
Current search:
novartis
×
pfizer
×
" seattle top stories "
×
unset
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More